broxuridine


Also found in: Wikipedia.

bromodeoxyuridine

A thymidine analogue which induces point mutations by tautomerisation. It is incorporated into DNA during the S-phase of the cell cycle, and used to study DNA replication, DNA synthesis by flow cytometry, and cell cycle and tumour kinetics.

broxuridine

Broxine, BUdR Oncology A radiation sensitizer used to treat malignant gliomas and other brain tumors
References in periodicals archive ?
The CRADA has provided NeoPharm with exclusive access to all clinical data generated in broxuridine studies conducted by various parties under the sponsorship of the NCI, involving more than 5,000 patients for prognostic applications.
In December 1996, NeoPharm filed a New Drug Application (NDA) with the FDA requesting marketing approval for broxuridine.
the wholly-owned subsidiary of BioChem Pharma (Nasdaq: BCHXF), under which BioChem will develop, market and distribute broxuridine in Canada.
Once broxuridine is marketed in Canada, the two companies will share product revenue.
Upon approval, NeoPharm expects to market broxuridine in the U.
AMEX: NEO, Nasdaq: NPRMW) announced that the Food and Drug Administration ("FDA") has accepted for review the company's New Drug Application ("NDA") covering use of broxuridine as a prognostic indicator in breast cancer.
We believe that broxuridine ("NEOMARK-BU(R)") provides a significant, rapid and reliable prognostic indicator which predicts patient survival and potential tumor recurrence.
NeoPharm is seeking FDA approval to market broxuridine for two separate indications: As a radiation sensitizer in the treatment of malignant gliomas or brain tumors (Broxine(TM)) and as an in-vivo prognostic test to measure tumor cell proliferation in breast cancer (NEOMARK-BU(R)).
The study of potential applications of broxuridine for use in cancer began over 30 years ago under the sponsorship of the National Cancer Institute ("NCI").
Broxuridine is one of a class of drugs known to be radiosensitizers.
In July, the company announced that it expects to file two New Drug Applications by the end of this year for Broxuridine ("BUdR"), a drug used as a radiosensitizer in the treatment of brain cancer and as a diagnostic aid in breast cancer.
Nasdaq: NPRM NPRMW) today announced that after meeting with the Oncology Division of the Food and Drug Administration ("FDA") last week, the Company expects to file two New Drug Applications ("NDA") for Broxuridine ("BUdR") by the end of the year.